• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经导管缘对缘修复治疗继发性二尖瓣反流死亡率的人工智能衍生风险评分:欧洲继发性二尖瓣反流风险评分(EuroSMR风险评分)

Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score.

作者信息

Hausleiter Jörg, Lachmann Mark, Stolz Lukas, Bedogni Francesco, Rubbio Antonio P, Estévez-Loureiro Rodrigo, Raposeiras-Roubin Sergio, Boekstegers Peter, Karam Nicole, Rudolph Volker

机构信息

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistr. 15, Munich D-81377, Germany.

German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

出版信息

Eur Heart J. 2024 Mar 14;45(11):922-936. doi: 10.1093/eurheartj/ehad871.

DOI:10.1093/eurheartj/ehad871
PMID:38243773
Abstract

BACKGROUND AND AIMS

Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary mitral regurgitation (SMR). This study sought to develop and validate an artificial intelligence-derived risk score (EuroSMR score) to predict 1-year outcomes (survival or survival + clinical improvement) in patients with SMR undergoing M-TEER.

METHODS

An artificial intelligence-derived risk score was developed from the EuroSMR cohort (4172 and 428 patients treated with M-TEER in the derivation and validation cohorts, respectively). The EuroSMR score was validated and compared with established risk models.

RESULTS

The EuroSMR risk score, which is based on 18 clinical, echocardiographic, laboratory, and medication parameters, allowed for an improved discrimination of surviving and non-surviving patients (hazard ratio 4.3, 95% confidence interval 3.7-5.0; P < .001), and outperformed established risk scores in the validation cohort. Prediction for 1-year mortality (area under the curve: 0.789, 95% confidence interval 0.737-0.842) ranged from <5% to >70%, including the identification of an extreme-risk population (2.6% of the entire cohort), which had a very high probability for not surviving beyond 1 year (hazard ratio 6.5, 95% confidence interval 3.0-14; P < .001). The top 5% of patients with the highest EuroSMR risk scores showed event rates of 72.7% for mortality and 83.2% for mortality or lack of clinical improvement at 1-year follow-up.

CONCLUSIONS

The EuroSMR risk score may allow for improved prognostication in heart failure patients with severe SMR, who are considered for a M-TEER procedure. The score is expected to facilitate the shared decision-making process with heart team members and patients.

摘要

背景与目的

对于二尖瓣经导管缘对缘修复术(M-TEER),风险分层在恰当选择重度继发性二尖瓣反流(SMR)患者的决策过程中至关重要。本研究旨在开发并验证一种人工智能衍生的风险评分(EuroSMR评分),以预测接受M-TEER的SMR患者的1年结局(生存或生存+临床改善)。

方法

从EuroSMR队列(分别在推导队列和验证队列中有4172例和428例接受M-TEER治疗的患者)中开发出一种人工智能衍生的风险评分。对EuroSMR评分进行验证,并与已建立的风险模型进行比较。

结果

基于18项临床、超声心动图、实验室和用药参数的EuroSMR风险评分,能够更好地区分存活和未存活患者(风险比4.3,95%置信区间3.7-5.0;P<.001),并且在验证队列中优于已建立的风险评分。1年死亡率的预测(曲线下面积:0.789,95%置信区间0.737-0.842)范围从<5%到>70%,包括识别出一个极高风险人群(占整个队列的2.6%),该人群1年内存活概率极低(风险比6.5,95%置信区间3.0-14;P<.001)。EuroSMR风险评分最高的前5%患者在1年随访时的死亡率为72.7%,死亡或无临床改善率为83.2%。

结论

EuroSMR风险评分可能有助于改善考虑接受M-TEER手术的重度SMR心力衰竭患者的预后。该评分有望促进与心脏团队成员和患者的共同决策过程。

相似文献

1
Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score.经导管缘对缘修复治疗继发性二尖瓣反流死亡率的人工智能衍生风险评分:欧洲继发性二尖瓣反流风险评分(EuroSMR风险评分)
Eur Heart J. 2024 Mar 14;45(11):922-936. doi: 10.1093/eurheartj/ehad871.
2
Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis.经导管二尖瓣置换或修复治疗继发性二尖瓣反流:一项倾向评分匹配分析。
Eur J Heart Fail. 2023 Mar;25(3):399-410. doi: 10.1002/ejhf.2797. Epub 2023 Mar 8.
3
Sex-Related Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation.经导管缘对缘修复术治疗继发性二尖瓣反流患者的性别相关临床特征和结局。
JACC Cardiovasc Interv. 2021 Apr 26;14(8):819-827. doi: 10.1016/j.jcin.2020.12.042. Epub 2021 Mar 31.
4
Guideline-directed medical therapy assessment in heart failure patients undergoing percutaneous mitral valve repair.指导下的医学治疗评估在接受经皮二尖瓣修复术的心衰患者中的应用。
ESC Heart Fail. 2024 Jun;11(3):1802-1807. doi: 10.1002/ehf2.14705. Epub 2024 Feb 13.
5
Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair.按改良纳入标准分层的二尖瓣缘对缘修复术后结局。
J Am Coll Cardiol. 2021 Dec 14;78(24):2408-2421. doi: 10.1016/j.jacc.2021.10.011.
6
Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation.经导管二尖瓣修复术治疗功能性心房性二尖瓣反流患者。
JACC Cardiovasc Imaging. 2022 Nov;15(11):1843-1851. doi: 10.1016/j.jcmg.2022.05.009. Epub 2022 Jul 13.
7
Sex-specific impact of anthropometric parameters on outcomes after transcatheter edge-to-edge repair for secondary mitral regurgitation.人体测量学参数对继发性二尖瓣反流经导管缘对缘修复术后结局的性别特异性影响。
Int J Cardiol. 2023 Jan 15;371:312-318. doi: 10.1016/j.ijcard.2022.09.028. Epub 2022 Sep 15.
8
A Score to Assess Mortality After Percutaneous Mitral Valve Repair.经皮二尖瓣修复术后死亡率评估评分。
J Am Coll Cardiol. 2022 Feb 15;79(6):562-573. doi: 10.1016/j.jacc.2021.11.041.
9
Derivation and Validation of a Clinical Risk Score for COAPT-Ineligible Patients Who Underwent Transcatheter Edge-to-Edge Repair.经导管缘对缘修复术禁忌患者的临床风险评分的推导和验证。
Am J Cardiol. 2023 Jan 1;186:100-108. doi: 10.1016/j.amjcard.2022.10.024. Epub 2022 Nov 8.
10
Staging Heart Failure Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.经导管缘对缘修复术治疗继发性二尖瓣反流的心力衰竭患者分期。
JACC Cardiovasc Interv. 2023 Jan 23;16(2):140-151. doi: 10.1016/j.jcin.2022.10.032. Epub 2022 Dec 28.

引用本文的文献

1
The multidisciplinary Heart Team in mitral valve transcatheter edge-to-edge repair.二尖瓣经导管缘对缘修复中的多学科心脏团队
Herz. 2025 Aug 28. doi: 10.1007/s00059-025-05328-8.
2
Utilizing multimodal artificial intelligence to advance cardiovascular diseases.利用多模态人工智能推进心血管疾病研究。
Precis Clin Med. 2025 Jul 17;8(3):pbaf016. doi: 10.1093/pcmedi/pbaf016. eCollection 2025 Sep.
3
Identifying Responders to Transcatheter Interventions for Secondary Mitral Regurgitation.识别二尖瓣反流继发性经导管介入治疗的反应者。
Curr Treat Options Cardiovasc Med. 2025;27(1):54. doi: 10.1007/s11936-025-01095-1. Epub 2025 Jul 31.
4
Diagnosis and Diagnostic Challenges of Secondary Mitral Regurgitation in the Era of Transcatheter Edge-to-Edge Repair of the Mitral Valve.二尖瓣经导管缘对缘修复时代继发性二尖瓣反流的诊断及诊断挑战
J Clin Med. 2025 Jun 26;14(13):4518. doi: 10.3390/jcm14134518.
5
Validation of the COAPT risk score in Polish patients undergoing transcatheter edge-to-edge repair of severe, functional mitral regurgitation: a multicenter, observational study.COAPT风险评分在接受经导管缘对缘修复严重功能性二尖瓣反流的波兰患者中的验证:一项多中心观察性研究。
Cardiol J. 2025;32(3):258-269. doi: 10.5603/cj.100877.
6
Machine-learning phenotyping of patients with functional mitral regurgitation undergoing transcatheter edge-to-edge repair: the MITRA-AI study.经导管缘对缘修复治疗功能性二尖瓣反流患者的机器学习表型分析:MITRA-AI研究
Eur Heart J Digit Health. 2025 Feb 13;6(3):340-349. doi: 10.1093/ehjdh/ztaf006. eCollection 2025 May.
7
Harnessing Artificial Intelligence for Innovation in Interventional Cardiovascular Care.利用人工智能推动介入性心血管护理创新。
J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102562. doi: 10.1016/j.jscai.2025.102562. eCollection 2025 Mar.
8
Clinical Characteristics, Outcomes, and Risk Stratification of Combined Mitral and Tricuspid Regurgitation: The China-VHD Study.二尖瓣和三尖瓣反流合并症的临床特征、结局及风险分层:中国瓣膜性心脏病研究
JACC Asia. 2025 Mar;5(3 Pt 2):436-452. doi: 10.1016/j.jacasi.2024.07.009. Epub 2024 Sep 10.
9
Implications of Tricuspid Regurgitation Severity in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair.经导管二尖瓣缘对缘修复患者三尖瓣反流严重程度的影响
J Am Heart Assoc. 2024 Dec 3;13(23):e037635. doi: 10.1161/JAHA.124.037635. Epub 2024 Nov 22.
10
Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair.经导管二尖瓣缘对缘修复领域的十大未来挑战。
J Clin Med. 2024 Mar 21;13(6):1799. doi: 10.3390/jcm13061799.